The Medicines Company today announced that it has received Paragraph IV Certification notice letters from Teva Parenteral Medicines, Inc. (TPM) and Pliva Hrvatska, d.o.o. (Pliva) notifying the Company that TPM and Pliva have submitted ANDAs to the U.S. FDA for approval to market generic versions of Angiomax. The Certification notice letters relate to U.S. patent No. 7,582,727, the recently issued product patent.
The details can be read here.
No comments:
Post a Comment